SNP_ID	Allele	Gene	Drug	Evidence_level	Efficacy	Dosage	Toxicity	Genotype	Description
rs2108622	C > T	CYP4F2	acenocoumarol	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs2108622	C > T	CYP4F2	acenocoumarol	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	acenocoumarol	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.
rs1056892	G > A	CBR3	anthracyclines and related substances	Level 2B	-	-	decreased	AA	                Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Patients with the AA genotype may still be at risk for adverse events when exposed to anthracyclines based on their genotype. Other genetic and clinical factors may also influence a patients risk for adverse events.
rs1045642	A > G	ABCB1	anthracyclines and related substances	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
rs1045642	A > G	ABCB1	antiepileptics	Level 3	increased	-	-	GG	                Genotype GG genotype  may be associated with decreased likelihood of drug resistance when treated with antiepileptics in people with Epilepsy in Asian as compared to genotype AA. However, this finding has been contradicted with many studies reporting no association between this variant and response to antiepileptics. Theres also a report showing that genotype GG is associated with increased likelihood of drug-resistance when treated with antiepileptics as compared to genotype AA in Caucasian patients. Other genetic and clinical factors may influence a patients response to antiepileptics.
rs1057910	A > C	CYP2C9	Antiinflammatory agents, non-steroids	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1042522	C > G	TP53	antineoplastic agents	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1800460	C > T	TPMT	azathioprine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	azathioprine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1045642	A > G	ABCB1	capecitabine	Level 3	-	-	increased	GG	                Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.
rs1045642	A > G	ABCB1	carbamazepine	Level 4	-	decreased	-	GG	                Patient with genotype GG may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory finding has been reported and no association has been found between the dose of carbamazepine and this variant. Other genetic and clinical factors may also influence the dose and response to carbamazepine...
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs1057910	A > C	CYP2C9	celecoxib	Level 2A	-	decreased	-	AC	                Patients with the AC genotype may have reduced metabolism of celecoxib and may require dose reduction when starting celecoxib therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to celecoxib.
rs1799853	C > T	CYP2C9	celecoxib	Level 3	decreased	-	-	CT	                Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to celecoxib.
rs4149056	T > C	SLCO1B1	cerivastatin	Level 2A	-	-	increased	CC	                Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.
rs1800460	C > T	TPMT	cisplatin	Level 3	-	-	increased	CT	                Patients with the TC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs1042522	C > G	TP53	cisplatin	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1695	A > G	GSTP1	cisplatin	Level 3	decreased	-	-	GG	                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.
rs1695	A > G	GSTP1	cisplatin	Level 3	decreased	-	-	GG	                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.
rs9332377	C > T	COMT	cisplatin	Level 1B	-	-	increased	TT	                Patients with the TT genotype who are treated with cisplatin may have an increased risk of hearing loss as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for hearing loss with cisplatin treatment.
rs1045642	A > G	ABCB1	cisplatin	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.
rs4244285	G > A	CYP2C19	clopidogrel	Level 1A	decreased	-	-	AA	                Patients with the AA genotype: 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for secondary cardiovascular events and response to clopidogrel.
rs1045642	A > G	ABCB1	clopidogrel	Level 2A	increased	-	-	GG	                People with GG  genotype may have decreased risk of cardiovascular death, myocardial infarction, or stroke when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes AA. Other genetic and clinical factors may also impact the response to clopidogrel.
rs1042522	C > G	TP53	cyclophosphamide	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1695	A > G	GSTP1	cyclophosphamide	Level 3	decreased	-	-	GG	                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide treatment.
rs1695	A > G	GSTP1	cyclophosphamide	Level 3	decreased	-	-	GG	                Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased progression free survival as compared to patients with the AA genotype. This association is contradicted in other studies. Other genetic and clinical factors may also influence a patients response to cisplatin and cyclophosphamide.
rs1695	A > G	GSTP1	cyclophosphamide	Level 2A	decreased	-	increased	GG	                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.
rs4244285	G > A	CYP2C19	cyclophosphamide	Level 4	-	-	decreased	AA	                Female patients with the AA genotype and Systemic Lupus Erythematosus who are treated with a high cumulative dose of cyclophosphamide (= or >23.75 g) may have a decreased risk of ovarian toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for cyclophosphamide-induced ovarian toxicity.
rs4244285	G > A	CYP2C19	cyclophosphamide	Level 4	decreased	-	-	AA	                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.
rs3745274	G > T	CYP2B6	cyclophosphamide	Level 3	-	-	decreased	GT	                Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patients risk for venoocclusive disease of the liver.
rs3745274	G > T	CYP2B6	cyclophosphamide	Level 3	-	decreased	-	GT	                Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients dose requirements.
rs1045642	A > G	ABCB1	cyclosporine	Level 3	-	decreased	-	GG	                Patients with genotype GG may have decreased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to patients with genotype AA or AG. However, contradictory findings have been reported for no association between this variant and dose/efficacy of cyclosporine. Other genetic and clinical factors may also influence the efficacy and dose of cyclosporine.
rs1045642	A > G	ABCB1	cytarabine	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
rs1045642	A > G	ABCB1	dexamethasone	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.
rs1057910	A > C	CYP2C9	diclofenac	Level 2A	-	-	increased	AC	                Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.
rs4244285	G > A	CYP2C19	doxorubicin	Level 4	decreased	-	-	AA	                Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients response to treatment.
rs1045642	A > G	ABCB1	doxorubicin	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.
rs1045642	A > G	ABCB1	doxorubicin	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
rs3745274	G > T	CYP2A7P1	efavirenz	Level 2A	-	-	increased	GT	                Patients with the GT genotype may have an increased risk of efavirenz-induced side effects (central nervous symptoms, fatigue, sleep disorder, liver toxicity or early termination of drug therapy) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1045642	A > G	ABCB1	efavirenz	Level 3	decreased	-	-	GG	                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.
rs1695	A > G	GSTP1	epirubicin	Level 2A	decreased	-	increased	GG	                Patients with the GG genotype and Breast Neoplasms who are treated with cyclophosphamide and epirubicin may have 1) decreased drug response 2) increased severity of toxicity as compared to patients with AG and AA genotype. Some patients were additionally treated with fluorouracil. Other genetic and clinical factors may influence a patients response to cyclophosphamide, epirubicin and fluorouracil.
rs1045642	A > G	ABCB1	epirubicin	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
rs1045642	A > G	ABCB1	fexofenadine	Level 3	-	-	-	GG	                Healthy individuals with the GG genotype who are treated with fexofenadine may have higher plasma drug levels as compared with healthy individuals with the AA genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.
rs1042522	C > G	TP53	fluorouracil	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1695	A > G	GSTP1	fluorouracil	Level 2A	increased	-	-	GG	                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.
rs1695	A > G	GSTP1	fluorouracil	Level 3	-	-	decreased	GG	                Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hematological toxicity when exposed to flourouracil.
rs1045642	A > G	ABCB1	fluorouracil	Level 3	increased	-	-	GG	                Patients with the GG genotype may have unfavorable prognosis (increased risk of lymph node metastases and decreased survival rate) when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence patients response to cisplatin and fluorouracil.
rs1045642	A > G	ABCB1	fluorouracil	Level 3	-	-	decreased	GG	                Patients with GG genotype may have decreased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also impact a patients response to fluorouracil.
rs17244841	A > T	HMGCR	fluvastatin	Level 2A	decreased	-	-	AT	                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.
rs4149056	T > C	SLCO1B1	hmg coa reductase inhibitors	Level 2A	-	-	increased	CC	                Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patients metabolism and response to statins.
rs17244841	A > T	HMGCR	hmg coa reductase inhibitors	Level 2A	decreased	-	-	AT	                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.
rs1045642	A > G	ABCB1	idarubicin	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have 1) decreased exposure to doxorubicin metabolites and 2) decreased response to anthracycline regimens as compared to patients with the AA genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to anthracycline regimens.
rs1057910	A > C	CYP2C9	losartan	Level 3	decreased	-	-	AC	                Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.
rs1800460	C > T	TPMT	mercaptopurine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	mercaptopurine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1695	A > G	GSTP1	methotrexate	Level 3	-	-	increased	GG	                Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patients level of methotrexate induced toxicity.
rs1045642	A > G	ABCB1	nelfinavir	Level 3	-	-	-	GG	                Patients with the GG genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have decreased CD4-cell count as compared to patients with the AA genotype 2) May have decreased virologic response as compared to patients with the AA genotype 3) May have a decreased, but not absent, risk for toxicity-related failure as compared to patients with the AA genotype, 4) May have an increased risk of hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients drug response or risk for toxicity.
rs1045642	A > G	ABCB1	nevirapine	Level 2A	-	-	increased	GG	                Patients with the GG genotype and HIV-1 infection who are treated with nevirapine may have an increased risk for nevirapine hepatotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for hepatotoxicity with nevirapine treatment.
rs1045642	A > G	ABCB1	nortriptyline	Level 3	-	-	decreased	GG	                Patients with the GG genotype and depression who are treated with nortriptyline may have a decreased, but not absent, likelihood to develop postural hypotension as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for postural hypotension with nortriptyline treatment.
rs7997012	A > G	HTR2A	olanzapine	Level 3	-	-	decreased	AG	                Patients with the AG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients risk for side effects with olanzapine treatment.
rs1695	A > G	GSTP1	oxaliplatin	Level 2A	increased	-	-	GG	                Patients with the GG genotype and colorectal cancer who are treated with fluorouracil and oxaliplatin may have a better treatment outcome (increased response, increased overall survival time, reduced risk of death) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to fluorouracil and oxaliplatin treatment.
rs1695	A > G	GSTP1	oxaliplatin	Level 3	-	-	increased	GG	                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.
rs1042522	C > G	TP53	paclitaxel	Level 2B	-	-	increased	CG	                Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to antineoplastic agents.
rs1045642	A > G	ABCB1	paclitaxel	Level 3	-	-	decreased	GG	                Patients with the GG genotype may have decreased risk of Neutropenia and Neurotoxicity Syndromes when treated with paclitaxel in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may influence the risk of adverse events to paclitaxel.
rs1045642	A > G	ABCB1	paclitaxel	Level 3	increased	-	-	GG	                Genotype GG may be associated with increased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype AG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.
rs11188072	C > T	CYP2C19	pantoprazole	Level 3	-	increased	-	CT	                Patients with the CT genotype who are treated with pantoprazole may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patients required dose and should be taken into consideration.
rs12979860	C > T	IL28B	peginterferon alfa-2a	Level 1A	decreased	-	-	CT	                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	peginterferon alfa-2a	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs12979860	C > T	IL28B	peginterferon alfa-2b	Level 1A	decreased	-	-	CT	                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	peginterferon alfa-2b	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs2108622	C > T	CYP4F2	phenprocoumon	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs2108622	C > T	CYP4F2	phenprocoumon	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1057910	A > C	CYP2C9	phenytoin	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patients response to phenytoin.
rs1799853	C > T	CYP2C9	phenytoin	Level 3	-	-	increased	CT	                Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patients response to phenytoin.
rs1045642	A > G	ABCB1	phenytoin	Level 3	decreased	-	-	GG	                Patients with genotype GG may have increased likelihood of drug resistance when treated with phenytoin in African American with Epilepsy as compared to patients with genotype AA. However, no association have been found between this variant and increased response to carbamazepine, phenobarbital, phenytoin and valproic acid in Asians.  Other genetic or clinical factors may influence a patients response to phenytoin.
rs1045642	A > G	ABCB1	phenytoin	Level 3	-	increased	-	GG	                Patients with genotype GG may have decreased plasma drug levels of phenytoin in people with no disease as compared to genotype AA. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patients dose of phenytoin.
rs1695	A > G	GSTP1	Platinum compounds	Level 3	-	-	increased	GG	                Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patients risk for adverse events with oxaliplatin or platinum compounds treatment.
rs17244841	A > T	HMGCR	pravastatin	Level 2A	decreased	-	-	AT	                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.
rs1800460	C > T	TPMT	purine analogues	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	purine analogues	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs4149056	T > C	SLCO1B1	repaglinide	Level 3	-	-	-	CC	                Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients response.
rs12979860	C > T	IL28B	ribavirin	Level 1A	decreased	-	-	CT	                Patients with the CT genotype may have decreased response to peginterferon alpha and ribavirin in people with Hepatitis C genotype 1 as compared to patients with the CC genotype. Patients with the CT genotype may also have lower spontaneous clearance in acute HCV infections than patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to peginterferon.
rs8099917	T > G	IL28B	ribavirin	Level 1B	decreased	-	-	GG	                Patients with the  GG genotype may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy in people with Chronic Hepatitis C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to peginterferon alfa and ribavirin therapy.
rs4149056	T > C	SLCO1B1	simvastatin	Level 1A	-	-	increased	CC	                Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs17244841	A > T	HMGCR	simvastatin	Level 2A	decreased	-	-	AT	                Patients with the AT genotype who are treated with statins may be less likely to respond as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response when treated with statins.
rs1800460	C > T	TPMT	thioguanine	Level 1A	-	-	increased	CT	                Patients with the CT genotype may have an increased risk for toxicity with thiopurine drugs and purine analogues as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1800462	C > G	TPMT	thioguanine	Level 1A	-	-	increased	GG	                Patients with the GG genotype (TPMT*2/*2): 1) may decreased deactivation of thiopurines 2) may have an increased risk for toxicity to thiopurines as compared to patients with the CC genotype (e.g. TPMT*1/*1). Other genetic and clinical factors may also influence a patients risk for toxicity.
rs1057910	A > C	CYP2C9	valproic acid	Level 3	-	-	increased	AC	                Patients with the AC genotype and with Epilepsy who are treated with valproic acid may have increased mean plasma drug concentrations of valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients response to valproic acid.
rs1045642	A > G	ABCB1	vincristine	Level 3	decreased	-	-	GG	                Patients with the GG genotype may have decreased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype AA. Other genetic and clinical factors may influence the patients response to dexamethasone, doxorubicin and vincristine.
rs7294	C > T	VKORC1	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype.
rs2108622	C > T	CYP4F2	warfarin	Level 1B	-	increased	-	CT	                Patients with the CT genotype who are taking an oral anticoagulant may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients required dose.
rs2108622	C > T	CYP4F2	warfarin	Level 1B	-	increased	-	TT	                Patients with the TT genotype who are taking an oral anticoagulant may require the highest dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patients required dose.
rs1799853	C > T	CYP2C9	warfarin	Level 1A	-	decreased	-	CT	                Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients dose of warfarin.
rs1057910	A > C	CYP2C9	warfarin	Level 1A	-	decreased	increased	AC	                Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.
